Investigating the anticancer properties of six benzothiazolopyrimidine derivatives on colon carcinoma cells, in vitro and in vivo
Journal of Biochemical and Molecular Toxicology · 2024
DOI: 10.1002/jbt.23779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2024. Verfasst von Melika Bakharzi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran. Hauptthemen laut MEDLINE: Pyrimidines, Antineoplastic Agents, Apoptosis, Colonic Neoplasms. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Ferdowsi University of Mashhad.
Abstract (Originalsprache)
Colorectal cancer (CRC) is the third most common cancer in the world. Despite considerable improvements in the treatment of this cancer, further research to discover novel and more effective agents is ongoing. In this study, possible cytotoxic and apoptotic properties of six benzothiazolopyrimidine derivatives were studied. To assess the IC 50 values of these agents, MTT assay was performed on HCT 116, CT26, and NIH/3T3 cells. Moreover, cell death mechanism induced by studied compounds was evaluated by PI/annexin V staining. Then, based on molecular docking results and in vitro experiments, the compounds with the highest anticancer properties were further analyzed in vivo in a mouse model of CRC. MTT results indicated that BTP(1) and BTP(4) had the highest selective cytotoxicity on colorectal cancer cells. Furthermore, flow cytometry results demonstrated a considerable increase in the percentage of the early apoptotic cells in BTP(1)‐ and BTP(4)‐treated groups. In vivo studies confirmed the antitumor properties of the two compounds by a significant regression in tumor size of BTP(1)‐ and BTP(4)‐treated mice compared to control groups. Histopathological examination of tumor tissues showed an increased number of apoptotic cells in these two groups compared to the control animals. Additionally, hematoxylin and eosin staining of the spleen and liver of treated mice did not exhibit considerable tissue damage. Thus, BTP(1) and BTP(4) can be considered promising agents in the treatment of colorectal cancer, although further experiments are required to assess their mechanism of action before their application in clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
- Department of Interdisciplinary Oncology, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
- Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
- Industrial Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
- Novel Diagnostics and Therapeutics Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
Förderung
- Ferdowsi University of Mashhad
Zitieren
APA
Bakharzi, M., Attar, E., Garmabi, H., Esmaeili, A. A., Bahrami, A. R., Danehchin, M., & Matin, M. M. (2024). Investigating the anticancer properties of six benzothiazolopyrimidine derivatives on colon carcinoma cells, in vitro and in vivo. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23779
Vancouver
Bakharzi M, Attar E, Garmabi H, Esmaeili AA, Bahrami AR, Danehchin M, et al. Investigating the anticancer properties of six benzothiazolopyrimidine derivatives on colon carcinoma cells, in vitro and in vivo. Journal of Biochemical and Molecular Toxicology. 2024. doi:10.1002/jbt.23779
BibTeX
@article{Bakharzi2024,
author = {Bakharzi, Melika and Attar, Elham and Garmabi, Hossein and Esmaeili, Abbas Ali and Bahrami, Ahmad Reza and Danehchin, Maryam and Matin, Maryam M},
title = {Investigating the anticancer properties of six benzothiazolopyrimidine derivatives on colon carcinoma cells, in vitro and in vivo},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2024},
doi = {10.1002/jbt.23779}
}
EUVIMED